We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Read MoreHide Full Article
Key Takeaways
Keros is focusing on rinvatercept as its lead wholly owned neuromuscular program for DMD and ALS.
KROS plans a DMD phase II start in Q3 2026, with initial patient data expected in the first half of 2027.
Phase I data showed muscle, fat and bone benefits, with no serious adverse events reported.
Keros Therapeutics (KROS - Free Report) is a clinical-stage biopharmaceutical company developing protein therapeutics that modulate transforming growth factor-beta family signaling across skeletal muscle, bone, and adipose tissue, among other areas.
Heading into 2026, the investment debate is increasingly centered on rinvatercept (KER-065) as Keros’ lead wholly owned neuromuscular program, with multiple near-term clinical and regulatory touchpoints that can reset expectations as plans move into execution.
KROS Pipeline Snapshot Heading Into 2026 Catalysts
Keros’ pipeline strategy emphasizes selectively targeting transforming growth factor-beta pathway ligands to restore tissue growth and repair. Within that framework, rinvatercept is now positioned as the lead wholly owned program for neuromuscular indications, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
The next leg of the story is catalyst-driven. Keros has mapped study starts and regulatory interactions that could broaden investor interest as timelines become more concrete. The setup also benefits from a leaner internal research and development base after elritercept responsibilities and costs transitioned to Takeda, which supports focus on rinvatercept execution.
Keros’ Rinvatercept Mechanism and What It Aims To Do
Rinvatercept is engineered to selectively bind and inhibit transforming growth factor-beta ligands, including myostatin (growth differentiation factor 8) and activin A. Keros views these ligands as key negative regulators of muscle and bone mass and strength.
By blocking these pathways, the company believes rinvatercept has the potential to promote skeletal muscle regeneration and increase muscle size and strength. The same thesis extends to reductions in body fat and muscle fibrosis, alongside enhanced overall bone strength, creating a mechanistic rationale that fits both DMD and ALS development plans.
Keros is initially targeting DMD, where corticosteroids are commonly used to manage the inflammatory component of the disease. In Keros’ framing, glucocorticoids are associated with significant long-term side effects, including muscle catabolism, increased fat accumulation, and accelerated bone loss.
That context matters for positioning. Rinvatercept’s design is aimed at biology tied to muscle, fat, fibrosis, and bone, which supports a differentiated add-on or alternative concept in DMD without making a commercial leap before controlled patient data.
Keros’ DMD Timeline With Orphan Status and Phase II Start
The timeline into 2026 includes a key regulatory milestone already secured. In August 2025, the Food and Drug Administration granted orphan drug designation to rinvatercept for the treatment of DMD.
Next, Keros plans to begin a phase II study in patients with DMD in the third quarter of 2026, with initial data expected in the first half of 2027. For investors, the phase II start can serve as validation that the program is moving from early signals to patient testing, while the initial readout is the first real checkpoint where expectations can be recalibrated based on human disease data rather than mechanism alone. Until then, continued development risk remains high because timelines and execution still drive the narrative.
KROS Plans for ALS and the Next Regulatory Checkpoint
Keros is also developing rinvatercept for ALS, and the next regulatory checkpoint is planned for the second half of 2026, when the company expects to engage with regulatory authorities to discuss phase II study design.
Design discussions matter because they can clarify the intended patient population, endpoints, and overall feasibility for moving the program forward. Even without projecting outcomes, a defined phase II framework can sharpen what the market watches next and how investors handicap the breadth of rinvatercept’s neuromuscular opportunity.
Keros’ Early Clinical Readouts That Support the Thesis
Keros shared new phase I data on March 9 that it said showed muscle, fat, and bone benefits, reinforcing its rationale for both DMD and ALS. The candidate was reported to be well-tolerated with no serious adverse events.
The company also reported increases in muscle mass, reduced fat, and higher bone density. In Keros’ framing, these signals align with target engagement and the intended downstream effects of inhibiting myostatin and activin A within the transforming growth factor-beta pathway.
KROS Risks Investors Need To Weigh in This Setup
The most visible risk is the competitive DMD landscape. Sarepta Therapeutics (SRPT - Free Report) has a DMD franchise that includes exon-skipping therapies and the gene therapy Elevidys, while PTC Therapeutics (PTCT - Free Report) markets Emflaza (deflazacort) for DMD. That competition can compress investor patience for early-stage timelines and raise the bar for differentiation.
Execution risk is another pressure point because rinvatercept is the focal program. Any slippage in planned starts or regulatory interactions could push catalysts out and weaken sentiment in the interim. Finally, Keros has not recorded product sales to date and remains dependent on partner-related revenues, which can make results volatile without a clear, repeatable near-term revenue engine.
View the Zacks #1 Rank List
Image: Bigstock
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Key Takeaways
Keros Therapeutics (KROS - Free Report) is a clinical-stage biopharmaceutical company developing protein therapeutics that modulate transforming growth factor-beta family signaling across skeletal muscle, bone, and adipose tissue, among other areas.
Heading into 2026, the investment debate is increasingly centered on rinvatercept (KER-065) as Keros’ lead wholly owned neuromuscular program, with multiple near-term clinical and regulatory touchpoints that can reset expectations as plans move into execution.
KROS Pipeline Snapshot Heading Into 2026 Catalysts
Keros’ pipeline strategy emphasizes selectively targeting transforming growth factor-beta pathway ligands to restore tissue growth and repair. Within that framework, rinvatercept is now positioned as the lead wholly owned program for neuromuscular indications, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
The next leg of the story is catalyst-driven. Keros has mapped study starts and regulatory interactions that could broaden investor interest as timelines become more concrete. The setup also benefits from a leaner internal research and development base after elritercept responsibilities and costs transitioned to Takeda, which supports focus on rinvatercept execution.
Keros’ Rinvatercept Mechanism and What It Aims To Do
Rinvatercept is engineered to selectively bind and inhibit transforming growth factor-beta ligands, including myostatin (growth differentiation factor 8) and activin A. Keros views these ligands as key negative regulators of muscle and bone mass and strength.
By blocking these pathways, the company believes rinvatercept has the potential to promote skeletal muscle regeneration and increase muscle size and strength. The same thesis extends to reductions in body fat and muscle fibrosis, alongside enhanced overall bone strength, creating a mechanistic rationale that fits both DMD and ALS development plans.
Keros Therapeutics, Inc. Price and Consensus
Keros Therapeutics, Inc. price-consensus-chart | Keros Therapeutics, Inc. Quote
KROS Is Targeting the DMD Treatment Gap
Keros is initially targeting DMD, where corticosteroids are commonly used to manage the inflammatory component of the disease. In Keros’ framing, glucocorticoids are associated with significant long-term side effects, including muscle catabolism, increased fat accumulation, and accelerated bone loss.
That context matters for positioning. Rinvatercept’s design is aimed at biology tied to muscle, fat, fibrosis, and bone, which supports a differentiated add-on or alternative concept in DMD without making a commercial leap before controlled patient data.
Keros’ DMD Timeline With Orphan Status and Phase II Start
The timeline into 2026 includes a key regulatory milestone already secured. In August 2025, the Food and Drug Administration granted orphan drug designation to rinvatercept for the treatment of DMD.
Next, Keros plans to begin a phase II study in patients with DMD in the third quarter of 2026, with initial data expected in the first half of 2027. For investors, the phase II start can serve as validation that the program is moving from early signals to patient testing, while the initial readout is the first real checkpoint where expectations can be recalibrated based on human disease data rather than mechanism alone. Until then, continued development risk remains high because timelines and execution still drive the narrative.
KROS Plans for ALS and the Next Regulatory Checkpoint
Keros is also developing rinvatercept for ALS, and the next regulatory checkpoint is planned for the second half of 2026, when the company expects to engage with regulatory authorities to discuss phase II study design.
Design discussions matter because they can clarify the intended patient population, endpoints, and overall feasibility for moving the program forward. Even without projecting outcomes, a defined phase II framework can sharpen what the market watches next and how investors handicap the breadth of rinvatercept’s neuromuscular opportunity.
Keros’ Early Clinical Readouts That Support the Thesis
Keros shared new phase I data on March 9 that it said showed muscle, fat, and bone benefits, reinforcing its rationale for both DMD and ALS. The candidate was reported to be well-tolerated with no serious adverse events.
The company also reported increases in muscle mass, reduced fat, and higher bone density. In Keros’ framing, these signals align with target engagement and the intended downstream effects of inhibiting myostatin and activin A within the transforming growth factor-beta pathway.
KROS Risks Investors Need To Weigh in This Setup
The most visible risk is the competitive DMD landscape. Sarepta Therapeutics (SRPT - Free Report) has a DMD franchise that includes exon-skipping therapies and the gene therapy Elevidys, while PTC Therapeutics (PTCT - Free Report) markets Emflaza (deflazacort) for DMD. That competition can compress investor patience for early-stage timelines and raise the bar for differentiation.
Execution risk is another pressure point because rinvatercept is the focal program. Any slippage in planned starts or regulatory interactions could push catalysts out and weaken sentiment in the interim. Finally, Keros has not recorded product sales to date and remains dependent on partner-related revenues, which can make results volatile without a clear, repeatable near-term revenue engine.
KROS Zacks Rank
Keros currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.